Novel research investigating the relationship between autoantibodies and idiopathic pulmonary fibrosis (IPF) may allow new therapies to be developed based on…
Maureen Newman
Maureen Newman is a science columnist for Pulmonary Hypertension News. She is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Maureen Newman
As the supplier of the body’s blood, the heart must also supply its own blood to keep itself nourished and oxygenated.
Targeting a mutation common to 15-40% of cases of idiopathic pulmonary arterial hypertension (PAH) with a specific drug target may…
Understanding the science behind chronic thromboembolic pulmonary hypertension (CTEPH) has come a long way since, originally, a diagnosis was made…
When exploring the origins of pulmonary arterial hypertension, researchers regard injuries to the endothelium of blood vessels as an important factor leading…
As more scientific studies are conducted to understand pulmonary hypertension, it is becoming more apparent that pulmonary arterial smooth muscle…
Researchers in Brazil and the United Kingdom have identified another reason to get up and get moving. In the report titled “…
Acute pulmonary arterial hypertension can result from metastatic cancer complications. Pulmonary tumor thrombotic microangiopathy (PTTM), which is one of these…
Two theories behind the pathogenesis of pulmonary arterial hypertension (PAH) converge on the protein known as the master transcription factor…
Patients with systemic sclerosis (SSc) are at an increased risk for mortality due to concurrent pulmonary hypertension or interstitial lung…
Representatives from Bayer HealthCare Pharmaceuticals presented findings at the American Thoracic Society’s (ATS) 2015 International Conference that suggest pulmonary hypertension is…
Bayer HealthCare will deliver six presentations at the ongoing American Thoracic Society (ATS) International Conference in Denver,…